115 related articles for article (PubMed ID: 3479624)
1. [Susceptibility of clinical isolates to aztreonam].
Asari S; Horikawa M; Tsukamoto H; Kouda K; Hayashi C; Miyai K
Jpn J Antibiot; 1987 Jul; 40(7):1317-31. PubMed ID: 3479624
[TBL] [Abstract][Full Text] [Related]
2. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
[TBL] [Abstract][Full Text] [Related]
3. [Antibacterial activities of monobactams against fresh clinical isolates].
Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
[TBL] [Abstract][Full Text] [Related]
4. [Susceptibility of clinical isolates to cefotaxime. Comparison to new antibiotics latamoxef, cefoperazone, and ceftizoxime].
Asari S; Horikawa M; Tsukamoto H; Shimizu Y; Koda K; Hayashi C; Miyai K
Jpn J Antibiot; 1984 Feb; 37(2):267-78. PubMed ID: 6330393
[TBL] [Abstract][Full Text] [Related]
5. [Susceptibility of clinical isolates to cefotaxime].
Asari S; Horikawa M; Tsukamoto H; Hayashi C; Miyai K
Jpn J Antibiot; 1983 Feb; 36(2):277-89. PubMed ID: 6304369
[TBL] [Abstract][Full Text] [Related]
6. [Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].
Okada K; Kawamura N; Ohkoshi M; Satake Y; Kawakita J
Jpn J Antibiot; 1982 Apr; 35(4):1009-21. PubMed ID: 6285019
[TBL] [Abstract][Full Text] [Related]
7. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1985). I. Susceptibility distribution].
Kosakai N; Kumamoto Y; Sakai S; Hirose T; Okayama S; Shigeta S; Shiraiwa Y; Yoshida H; Miura Y; Ogata M
Jpn J Antibiot; 1987 Dec; 40(12):1975-2011. PubMed ID: 3448255
[TBL] [Abstract][Full Text] [Related]
8. [Antibacterial activity of aztreonam against clinical isolates].
Igari J
Jpn J Antibiot; 1994 May; 47(5):502-20. PubMed ID: 8051793
[TBL] [Abstract][Full Text] [Related]
9. [Susceptibility of clinical isolates to aztreonam].
Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria.
Shibl AM; Ishag AH; Durgham SM
Chemotherapy; 1989; 35 Suppl 1():72-6. PubMed ID: 2659292
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of in vitro activity of first, second and third generation cephem antibiotics against various pathogens isolated from clinical materials in 1983].
Matsuo K; Tsuzaki Y; Furukawa S; Uete T
Jpn J Antibiot; 1984 Jun; 37(6):1040-57. PubMed ID: 6387213
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibility of clinically isolated strains to aztreonam].
Daimon Y
Jpn J Antibiot; 1988 Nov; 41(11):1623-34. PubMed ID: 3145344
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial activity of aztreonam: a synthetic monobactam. A comparative study with thirteen other antibiotics.
Paradelis AG; Stathopoulos GA; Salpigides GN; Crassaris LG
Methods Find Exp Clin Pharmacol; 1983; 5(6):375-83. PubMed ID: 6684718
[TBL] [Abstract][Full Text] [Related]
14. [Antimicrobial activity of sulbactam/cefoperazone. Comparison with other new cephems].
Deguchi K; Yokota N; Koguchi M; Fukayama S; Nishimura Y; Nakane Y; Oda S; Tanaka S; Kato M; Sato K
Jpn J Antibiot; 1987 Oct; 40(10):1752-61. PubMed ID: 3444015
[TBL] [Abstract][Full Text] [Related]
15. [Clinical laboratory approach for estimating the effective administrative dose of latamoxef. Significance of a 4-category system interpretation of the latamoxef disc susceptibility test].
Uete T; Matsuo K
Jpn J Antibiot; 1987 Nov; 40(11):1906-16. PubMed ID: 3327966
[TBL] [Abstract][Full Text] [Related]
16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1985). III. Secular changes in susceptibility].
Kosakai N; Kumamoto Y; Sakai S; Hirose T; Okayama S; Shigeta S; Shiraiwa Y; Yoshida H; Miura Y; Ogata M
Jpn J Antibiot; 1987 Dec; 40(12):2026-142. PubMed ID: 3448256
[TBL] [Abstract][Full Text] [Related]
17. [Susceptibility of clinical bacterial isolates to aztreonam].
Murase M; Niiya T; Takeuchi N
Jpn J Antibiot; 1987 Sep; 40(9):1698-706. PubMed ID: 3121888
[TBL] [Abstract][Full Text] [Related]
18. [Combination action of sisomicin, dibekacin and cefotetan, cefotaxime, latamoxef, and cefsulodin against Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa].
Saito M; Azuma K; Nishino T; Tanino T
Jpn J Antibiot; 1983 Oct; 36(10):2833-43. PubMed ID: 6325746
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of in vitro antibacterial activities of new cephems against clinical organisms (isolated between June 1983 and January 1984)].
Tsuji A; Goto S; Sato K; Tomizawa M; Hasebe S; Takagi T; Yatagai S; Kanno H; Ozaki K; Yakata M
Jpn J Antibiot; 1985 Aug; 38(8):2171-84. PubMed ID: 3908734
[TBL] [Abstract][Full Text] [Related]
20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
